New study provides good results for Eli Lilly and Boehringer

Eli Lilly's diabetes pill Jardiance showed a 21 percent reduction in deaths and hospitalizations of adult patients with heart failure with preserved ejection fraction (HFpEF) compared to a placebo, the pharmaceutical company reported on Friday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app